Brokerages Set Recro Pharma Inc (REPH) Target Price at $19.67

Recro Pharma Inc (NASDAQ:REPH) has been given an average recommendation of “Buy” by the seven research firms that are presently covering the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $18.00.

A number of equities analysts have commented on the company. Aegis reissued a “buy” rating and set a $11.00 target price on shares of Recro Pharma in a report on Monday, March 27th. Zacks Investment Research cut Recro Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, March 21st.

Shares of Recro Pharma (NASDAQ:REPH) traded up 0.25% during midday trading on Wednesday, reaching $7.92. The company had a trading volume of 23,694 shares. The firm’s market capitalization is $150.88 million. The company has a 50 day moving average of $7.97 and a 200 day moving average of $7.73. Recro Pharma has a 12-month low of $5.89 and a 12-month high of $12.50.

COPYRIGHT VIOLATION WARNING: This story was originally posted by BBNS and is owned by of BBNS. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://baseballnewssource.com/markets/recro-pharma-inc-reph-receives-19-67-average-price-target-from-brokerages-updated-updated/525289.html.

In related news, major shareholder Scp Vitalife Partners (Israel) sold 4,030 shares of the stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $7.89, for a total value of $31,796.70. Following the completion of the sale, the insider now owns 772,714 shares of the company’s stock, valued at $6,096,713.46. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Scp Vitalife Partners Ii Lp sold 9,983 shares of the stock in a transaction that occurred on Friday, February 17th. The shares were sold at an average price of $7.59, for a total value of $75,770.97. Following the completion of the sale, the insider now directly owns 2,292,899 shares of the company’s stock, valued at approximately $17,403,103.41. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,990 shares of company stock valued at $467,384. Insiders own 39.30% of the company’s stock.

Large investors have recently bought and sold shares of the company. Numeric Investors LLC acquired a new stake in Recro Pharma during the fourth quarter valued at about $556,000. Deerfield Management Co. acquired a new stake in Recro Pharma during the fourth quarter valued at about $16,725,000. Kingdon Capital Management L.L.C. boosted its stake in Recro Pharma by 170.5% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 311,072 shares of the specialty pharmaceutical company’s stock valued at $2,507,000 after buying an additional 196,072 shares during the period. Alyeska Investment Group L.P. boosted its stake in Recro Pharma by 1,571.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 862,761 shares of the specialty pharmaceutical company’s stock valued at $6,954,000 after buying an additional 811,142 shares during the period. Finally, Broadfin Capital LLC boosted its stake in Recro Pharma by 26.5% in the fourth quarter. Broadfin Capital LLC now owns 3,100,086 shares of the specialty pharmaceutical company’s stock valued at $24,987,000 after buying an additional 650,000 shares during the period. 53.23% of the stock is owned by institutional investors.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

5 Day Chart for NASDAQ:REPH

Receive News & Ratings for Recro Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc and related companies with our FREE daily email newsletter.

 


Latest News

Gift Ngoepe Becomes First African to Play in MLB
Gift Ngoepe Becomes First African to Play in MLB
Eric Thames Pulled From Game With Tightness in Hamstring
Eric Thames Pulled From Game With Tightness in Hamstring
Julio Urias Returning to Dodgers Thursday
Julio Urias Returning to Dodgers Thursday
Tony Gwynn Jr. Like Father Like Son in Baseball and Brewing
Tony Gwynn Jr. Like Father Like Son in Baseball and Brewing
Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Colorado Rockies Bullpen Helping Them to NL West Lead
Colorado Rockies Bullpen Helping Them to NL West Lead


Leave a Reply

 
© 2006-2017 BBNS.